id: pharmacogenetic_testing_access_to_quality_adjusted_life_years_aud
name: Access to Pharmacogenetic Testing Infrastructure â†’ Quality-Adjusted Life Years
  in Alcohol Use Disorder Patients
from_node:
  node_id: pharmacogenetic_testing_access
  node_name: Access to Pharmacogenetic Testing Infrastructure
to_node:
  node_id: quality_adjusted_life_years_aud
  node_name: Quality-Adjusted Life Years in Alcohol Use Disorder Patients
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Healthcare system implements pharmacogenetic testing infrastructure enabling
  OPRM1 genotype screening for alcohol use disorder patients'
- 'Step 2: Genetic testing results guide clinical decision-making for medication selection
  (naltrexone vs acamprosate)'
- 'Step 3: Personalized medication allocation improves treatment efficacy and reduces
  adverse medication-related outcomes in matched patient subgroups'
- 'Step 4: Improved treatment response translates to increased quality-adjusted life
  years through reduced relapse, better functioning, and improved quality of life'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: R. L. Sluiter et al. 2018. "Cost-Effectiveness Analysis of Genotype-Guided
    Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or
    Acamprosate, Using a Modeling Approach." *European Addiction Research*. https://doi.org/10.1159/000494127
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.660410'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: healthcare_system_reimbursement_policy
  direction: strengthens
  strength: strong
  description: Whether genetic testing and personalized medication allocation are
    covered by insurance or national health systems determines accessibility and population-level
    impact
- name: baseline_relapse_risk_differential
  direction: strengthens
  strength: strong
  description: The magnitude of difference in relapse rates between genotype-matched
    and non-matched treatment allocation drives the cost-effectiveness and clinical
    benefit of the intervention
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/pharmacogenetic_testing_access_to_quality_adjusted_life_years_aud.yaml
_category: healthcare_access
